vs
Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $112.4M, roughly 1.6× BYLINE BANCORP, INC.). BYLINE BANCORP, INC. runs the higher net margin — 33.4% vs 1.6%, a 31.8% gap on every dollar of revenue. On growth, BYLINE BANCORP, INC. posted the faster year-over-year revenue change (9.0% vs 5.0%). Over the past eight quarters, BYLINE BANCORP, INC.'s revenue compounded faster (6.4% CAGR vs -0.2%).
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
BY vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $112.4M | $177.4M |
| Net Profit | $37.6M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 33.4% | 1.6% |
| Revenue YoY | 9.0% | 5.0% |
| Net Profit YoY | 33.0% | — |
| EPS (diluted) | $0.83 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $112.4M | $177.4M | ||
| Q4 25 | $117.0M | $196.9M | ||
| Q3 25 | $115.7M | $179.5M | ||
| Q2 25 | $110.5M | $181.1M | ||
| Q1 25 | $103.1M | $168.9M | ||
| Q4 24 | $104.7M | $187.3M | ||
| Q3 24 | $101.8M | $168.6M | ||
| Q2 24 | $99.4M | $178.0M |
| Q1 26 | $37.6M | $2.9M | ||
| Q4 25 | $34.5M | — | ||
| Q3 25 | $37.2M | $5.4M | ||
| Q2 25 | $30.1M | $-4.8M | ||
| Q1 25 | $28.2M | $4.8M | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $30.3M | $-143.5M | ||
| Q2 24 | $29.7M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 40.1% | 1.2% | ||
| Q3 25 | 43.1% | 3.5% | ||
| Q2 25 | 35.2% | 4.7% | ||
| Q1 25 | 36.4% | 1.2% | ||
| Q4 24 | 38.6% | 13.2% | ||
| Q3 24 | 39.3% | -82.8% | ||
| Q2 24 | 40.4% | 15.9% |
| Q1 26 | 33.4% | 1.6% | ||
| Q4 25 | 34.1% | — | ||
| Q3 25 | 32.1% | 3.0% | ||
| Q2 25 | 27.2% | -2.7% | ||
| Q1 25 | 27.4% | 2.8% | ||
| Q4 24 | 34.3% | — | ||
| Q3 24 | 29.8% | -85.1% | ||
| Q2 24 | 29.9% | 10.6% |
| Q1 26 | $0.83 | $0.07 | ||
| Q4 25 | $0.77 | $0.05 | ||
| Q3 25 | $0.82 | $0.12 | ||
| Q2 25 | $0.66 | $-0.11 | ||
| Q1 25 | $0.64 | $0.10 | ||
| Q4 24 | $0.68 | $0.38 | ||
| Q3 24 | $0.69 | $-3.11 | ||
| Q2 24 | $0.68 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.4M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $653.9M |
| Total Assets | $9.9B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.4M | $144.3M | ||
| Q4 25 | $149.1M | $238.4M | ||
| Q3 25 | $259.0M | $246.3M | ||
| Q2 25 | $218.3M | $445.9M | ||
| Q1 25 | $421.3M | $493.6M | ||
| Q4 24 | $563.1M | $484.6M | ||
| Q3 24 | $452.6M | $453.8M | ||
| Q2 24 | $730.5M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.3B | $653.9M | ||
| Q4 25 | $1.3B | $693.1M | ||
| Q3 25 | $1.2B | $727.2M | ||
| Q2 25 | $1.2B | $757.8M | ||
| Q1 25 | $1.1B | $798.5M | ||
| Q4 24 | $1.1B | $778.3M | ||
| Q3 24 | $1.1B | $749.6M | ||
| Q2 24 | $1.0B | $879.3M |
| Q1 26 | $9.9B | $1.2B | ||
| Q4 25 | $9.7B | $1.3B | ||
| Q3 25 | $9.8B | $1.3B | ||
| Q2 25 | $9.7B | $1.5B | ||
| Q1 25 | $9.6B | $1.6B | ||
| Q4 24 | $9.5B | $1.6B | ||
| Q3 24 | $9.4B | $1.5B | ||
| Q2 24 | $9.6B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BY
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
